Story perspectives

Supreme Court Hears Vascepa “Skinny Label” Price Fight

5/1/2026

Summary

Story summary

The Supreme Court heard oral arguments on April 29, 2026 in Hikma v. Amarin concerning Vascepa’s “skinny labeling.”
The case asks whether Hikma’s label for severe hypertriglyceridemia urges doctors to use the still-patented, less-severe indication.
Amarin alleges patent infringement; Hikma and the government say limiting skinny labels would raise drug prices.
Hikma says labeling saved Medicare $1.5 billion and generics $2.9 trillion, while Amarin posted $213.6 million and experts warn a ruling could keep prices high.

1 of 1

Story summary

The Supreme Court heard oral arguments on April 29, 2026 in Hikma v. Amarin concerning Vascepa’s “skinny labeling.”
The case asks whether Hikma’s label for severe hypertriglyceridemia urges doctors to use the still-patented, less-severe indication.
Amarin alleges patent infringement; Hikma and the government say limiting skinny labels would raise drug prices.
Hikma says labeling saved Medicare $1.5 billion and generics $2.9 trillion, while Amarin posted $213.6 million and experts warn a ruling could keep prices high.